Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus

Steven P. Sparagana; David C. Wilkes; Catherine E. Thompson; Daniel C. Bowers

doi:10.1016/j.pediatrneurol.2010.01.016

Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus

Steven P. Sparagana, David C. Wilkes, Catherine E. Thompson, Daniel C. Bowers

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A 12-year-old girl with clinically established tuberous sclerosis complex, and without signs of neurofibromatosis type 1, developed a right retro-ocular optic nerve tumor. After rapid growth for 1 year after its discovery, the optic nerve tumor demonstrated modest progression. The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors. Although her left ventricular subependymal giant cell tumor demonstrated a 49% reduction in volume, the optic nerve tumor did not respond, and even underwent slight (6%) growth during the 16-month treatment. The quality of this child's vision has remained normal in both eyes, and she is otherwise asymptomatic with regard to the optic nerve tumor.

Original language	English (US)
Pages (from-to)	443-446
Number of pages	4
Journal	Pediatric Neurology
Volume	42
Issue number	6
DOIs	https://doi.org/10.1016/j.pediatrneurol.2010.01.016
State	Published - Jun 2010

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Neurology
Developmental Neuroscience
Clinical Neurology

Access to Document

10.1016/j.pediatrneurol.2010.01.016

Cite this

@article{59727aaf402248bfaa7b8ef0b780f2ae,

title = "Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus",

abstract = "A 12-year-old girl with clinically established tuberous sclerosis complex, and without signs of neurofibromatosis type 1, developed a right retro-ocular optic nerve tumor. After rapid growth for 1 year after its discovery, the optic nerve tumor demonstrated modest progression. The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors. Although her left ventricular subependymal giant cell tumor demonstrated a 49% reduction in volume, the optic nerve tumor did not respond, and even underwent slight (6%) growth during the 16-month treatment. The quality of this child's vision has remained normal in both eyes, and she is otherwise asymptomatic with regard to the optic nerve tumor.",

author = "Sparagana, {Steven P.} and Wilkes, {David C.} and Thompson, {Catherine E.} and Bowers, {Daniel C.}",

year = "2010",

month = jun,

doi = "10.1016/j.pediatrneurol.2010.01.016",

language = "English (US)",

volume = "42",

pages = "443--446",

journal = "Pediatric Neurology",

issn = "0887-8994",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus

AU - Sparagana, Steven P.

AU - Wilkes, David C.

AU - Thompson, Catherine E.

AU - Bowers, Daniel C.

PY - 2010/6

Y1 - 2010/6

N2 - A 12-year-old girl with clinically established tuberous sclerosis complex, and without signs of neurofibromatosis type 1, developed a right retro-ocular optic nerve tumor. After rapid growth for 1 year after its discovery, the optic nerve tumor demonstrated modest progression. The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors. Although her left ventricular subependymal giant cell tumor demonstrated a 49% reduction in volume, the optic nerve tumor did not respond, and even underwent slight (6%) growth during the 16-month treatment. The quality of this child's vision has remained normal in both eyes, and she is otherwise asymptomatic with regard to the optic nerve tumor.

AB - A 12-year-old girl with clinically established tuberous sclerosis complex, and without signs of neurofibromatosis type 1, developed a right retro-ocular optic nerve tumor. After rapid growth for 1 year after its discovery, the optic nerve tumor demonstrated modest progression. The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors. Although her left ventricular subependymal giant cell tumor demonstrated a 49% reduction in volume, the optic nerve tumor did not respond, and even underwent slight (6%) growth during the 16-month treatment. The quality of this child's vision has remained normal in both eyes, and she is otherwise asymptomatic with regard to the optic nerve tumor.

UR - http://www.scopus.com/inward/record.url?scp=77952107081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952107081&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2010.01.016

DO - 10.1016/j.pediatrneurol.2010.01.016

M3 - Article

C2 - 20472200

AN - SCOPUS:77952107081

SN - 0887-8994

VL - 42

SP - 443

EP - 446

JO - Pediatric Neurology

JF - Pediatric Neurology

IS - 6

ER -

Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this